A Safety Study of LY3372689 Given By Mouth to Healthy Participants

Lilly logo

Lilly

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: LY3372689
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03819270
I9X-MC-MTAA (Other Identifier)
17219

Details and patient eligibility

About

This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive up to 3 doses of LY3372689 or placebo. The study will last about 12 weeks, including screening.

Enrollment

23 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Overtly healthy male or a female who cannot get pregnant
  • Have a body mass index (BMI) of at least 18.5 kilogram per square meter (kg/m²), inclusive, at screening
  • Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
  • Have veins suitable for ease of blood sampling

Exclusion criteria

  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure
  • Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Have long exposure to sunlight routinely or use tanning beds regularly

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

23 participants in 2 patient groups, including a placebo group

LY3372689
Experimental group
Description:
Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
Treatment:
Drug: LY3372689
Placebo
Placebo Comparator group
Description:
Matching placebo administered orally in healthy participants in one of three study periods
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems